Highest-materiality recent filing
Q/C Technologies terminates crypto mining license, pivots to optical AI computing
Terminated Technology License and Development Agreement with LightSolver Ltd. effective June 26, 2026; LPU subsidiary relieved from milestone payments.
Q/C Technologies hires Martin Shkreli as strategic advisor; issues warrants and restricted shares
Monthly consulting fee of $12,500 ($150,000 annually) to Ocean Avenue Holdings, Shkreli's entity.
Reverse stock split approved at ratio from 1-for-2 to 1-for-250, with Board discretion.
Issued 400k warrants to James Altucher/Z-List Media with exercise prices $5-$10 over 2-year term.
Name changed from TNF Pharmaceuticals to Q/C Technologies effective September 22, 2025.
TNF Pharma closes $7M private placement at 44% premium; closes LPU acquisition
Closed $7M private placement of 7,000 Series H preferred shares convertible to 1.4M common at $5.00/share, plus warrants for 1.4M shares at $5.00.
TNF to acquire 100% of LPU Holdings LLC; closing consideration is Series I Convertible Preferred Stock convertible into 747,362 common shares.
TNF Pharma raises $7M, acquires LPU Holdings for crypto mining, ends sarcopenia trial
$7M private placement: Series H convertible preferred (7% dividend, $5 conversion) and warrants for 1.4M shares at $5; expected close Sept 4, 2025.
Authorized common shares increased from 250M to 1.25B, filed June 6, 2025.
TNF Pharma receives Nasdaq bid price deficiency notice; 180 days to cure
Received Nasdaq letter on March 17, 2025 for failure to maintain minimum $1.00 bid price over 30 consecutive business days.
TNF Pharmaceuticals shareholders approve 15x increase in authorized common stock to 250M shares
Authorized common shares increased from 16,666,666 to 250,000,000; amendment filed July 25, 2024.
On June 17, 2024, MyMD filed a Certificate of Amendment to increase authorized Series G Convertible Preferred Stock from 8,950 to 12,826,273 shares.
Corrected typographical errors in terms of Series G and Series F-1 Preferred Stock and Warrants from May 20, 2024 private placements.
MyMD appoints Glass as President/CMO, Friscia to board; Chapman departs; preferred shares increased
Mitchell Glass, M.D. appointed President & CMO effective June 13, 2024; no additional compensation.
MyMD completes $14M private placement of Series G and F-1 preferred stock and warrants
Gross proceeds of $14 million from two concurrent private placements announced May 20.
MyMD raises $13.9M via Series G & F-1 preferred stock and warrants
Gross proceeds of $8.9M (Series G) and $5.0M (Series F-1) from private placement of convertible preferred and warrants at $1.816/share.
Deferred March and April 2024 installment payments on Series F Preferred Stock to May 1, 2024, and waived related breaches.
MyMD Pharmaceuticals regains Nasdaq minimum bid price compliance after reverse stock split
Received notice from Nasdaq on March 4, 2024 that it has regained compliance with Listing Rule 5550(a)(2).
MyMD Pharma gains FDA clearance for Phase 2 trial of oral MYMD-1 in rheumatoid arthritis
FDA cleared IND for Phase 2 trial of oral MYMD-1 (TNF-α inhibitor) in rheumatoid arthritis.
MyMD Supera-CBD preclinical study shows rapid pain relief; Japanese patent granted
Supera-CBD reduced acute inflammatory heat pain within 60 minutes; relief lasted up to five hours; traditional CBD had no effect.
MyMD Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq letter on Oct 11, 2023, for failing to maintain $1.00 closing bid price for 30 consecutive business days.
Cohort 4 (1050mg) showed reduction in TNF-α over 28 days vs placebo (p=0.002 to 0.008).
FDA accepts MyMD IND for Phase 2 study of oral TNF-α inhibitor MYMD-1 in rheumatoid arthritis
FDA acceptance allows Phase 2 trial in RA; MyMD will discuss timing with CRO IQVIA.
MyMD announces positive Phase 2 topline results for MYMD-1 in sarcopenia/frailty
Study met primary endpoints: significantly reduced TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) levels.
MyMD still awaiting Phase 2 data for MYMD-1 sarcopenia trial completed June 2023
Phase 2 trial of MYMD-1 for sarcopenia completed in June 2023; data not received as of July 14.
MyMD doses 37 of 40 patients in Phase 2 trial of MYMD-1 for sarcopenia/frailty; no safety issues
Safety Review Committee confirms no safety/toxicity issues with first 30 patients; unanimous vote to escalate to final dose level.
MyMD Pharmaceuticals announces positive preclinical data for MYMD-1 in RA model
MYMD-1 reduced histopathological changes vs placebo (p<0.0001 composite score) in RA model.
On June 13, 2024, Mr. Stephen Friscia was appointed to serve as a member of the Board until his successor has been duly elected and qualified or until his earlier resignation or removal.
the Company and Christopher Chapman, M.D. mutually agreed on the separation of Dr. Chapman from his position as President, Chief Medical Officer and member of the board of directors
On June 13, 2024, the Company appointed Mitchell Glass, M.D., a current member of the Board, to the positions of President and Chief Medical Officer, effective as of June 13, 2024.
On April 15, 2024, Adam Kaplin, M.D., Ph.D., who served as Chief Scientific Officer of MyMD Pharmaceuticals, Inc. (the “Company”), tendered his resignation from his role as an officer of the Company, effective immediately.
the Company increased the authorized number of directors from six (6) to seven (7) and appointed Mitchell Glass to serve as a member of the Company’s board of directors
providing that Mr. Rivard be appointed as the Company’s Chief Legal Officer and that his annual base salary be set at $275,000, effective retroactively to January 1, 2023.
On September 1, 2021, Robert C. Schroeder, who served as a member of the board of directors of MyMD Pharmaceuticals, Inc. (the “Company”), passed away.
Max materiality 0.85 · Median 0.60 · Most common event other_material